Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CureVac N.V. - Ordinary Shares (NQ: CVAC )

3.650 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CureVac N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
CureVac Streamlines European Network for mRNA Product Manufacturing
- CureVac right-sizes manufacturing network to adapt to changes in vaccine peak demands - Demand reassessed for first-generation COVID-19 vaccine candidate, CVnCoV, currently under regulatory review... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
CureVac's CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 31, 2021 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
Glaxo, SK Bioscience Start COVID-19 Vaccine Trial Against AstraZeneca Shot
GlaxoSmithKline Plc (NYSE: GSK) has started Phase 3 clinical study for a COVID-19 vaccine candidate designed by South Korean drugmaker SK Bioscience Co. The... 
Via Benzinga
Exposures COVID-19
Unusual Options Activity Insight: CureVac
CureVac (NASDAQ:CVAC) shares experienced unusual options ... 
Via Benzinga
CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic
- Findings in preclinical mouse models provide first direct proof of efficacy of HNF4A mRNA therapeutics in the treatment of liver fibrosis and cirrhosis - Further research aimed at optimizing mRNA... 
From CureVac
Via AccessWire
Topics Death Intellectual Property Regulatory Compliance
Exposures COVID-19 Death Intellectual Property
Could CureVac's Canceled Deal Spell Trouble for Other mRNA Cancer Vaccines?
It isn't likely. 
Via The Motley Fool
Surprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now
The least expensive COVID-19 vaccine stock right now isn't one of the leaders in the market -- at least not yet. 
Via The Motley Fool
Exposures COVID-19
4 High-Yield Dividend Stocks to Boost Your Dividend Income
Dividends paid by GlaxoSmithKline plc, Vector Group Ltd, Star Group, L.P., and Ennis, Inc translate to high yields at their current price levels. 
Via Talk Markets
Boehringer Ingelheim Scraps Lung Cancer Program With CureVac
CureVac NV (NASDAQ: CVAC) disclosed among the COVID-19 vaccine highlights that €465 million oncology partnership with Boehringer Ingelheim had been terminated... 
Via Benzinga
Exposures COVID-19
Vaccine Stocks: The Latest News Moving BNTX, CVAC, NVAX Stocks Today
Today, investors in vaccine stocks are seeing a lot of red, as investors seem to be taking some risk off the table ahead of Fed tapering. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update
CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update - Continuation of corporate transformation into commercial-ready biopharma company-... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study
- Preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac's first-generation mRNA... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
26 Stocks Moving in Thursday's Pre-Market Session
Gainers Ensysce Biosciences, Inc. (NASDAQ: ENSC) shares rose 34% to $5.48 in pre-market trading after dropping around 15% on Wednesday. Ensysce Biosciences recently appointed... 
Via Benzinga
EMA Starts Rolling Review Of Glaxo - Sanofi COVID-19 Vaccine
EMA's human medicines committee has kicked off a rolling review of a COVID-19 vaccine from Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (... 
Via Benzinga
Exposures COVID-19
Can CureVac Win Market Share With Only 48% Vaccine Efficacy?
CureVac aims to become one of Europe's big suppliers. 
Via The Motley Fool
Unusual Options Activity Insight: CureVac
On Wednesday, shares of CureVac (NASDAQ:CVAC) saw unusual options activity. After the option alert, the stock price moved down to $59.8. Sentiment: BEARISH Option Type: SWEEP... 
Via Benzinga
South Korea Negotiating With mRNA COVID-19 Vaccine Makers To Produce Up To 1B Doses: Reuters
South Korea is reportedly in talks with mRNA vaccine makers, including Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA), to produce COVID-19 shots in the... 
Via Benzinga
Exposures COVID-19
Here's Why You Should Avoid CureVac Stock Like the Plague
Funds will not be safe if invested in this coronavirus stock. 
Via The Motley Fool
Exposures COVID-19
Is CureVac a Bargain Bet on mRNA Vaccine Technology?
CureVac shares have slipped more than 20% on bad news. 
Via The Motley Fool
Topics Cannabis
Exposures COVID-19 Cannabis
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision And Conference Presentations In A Light Week
Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few COVID-19 disappointments,... 
Via Talk Markets
Exposures COVID-19 Product Safety
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision, Conference Presentations In A Light Week
Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few... 
Via Benzinga
Exposures Product Safety
Moderna and Pfizer May Benefit From This Rival's Bad News
And it could equal billions of dollars for these vaccine leaders. 
Via The Motley Fool
Topics Cannabis
Exposures COVID-19 Cannabis
Can CureVac Recover After Its Vaccine Setback?
Investors' dreams of a third strong mRNA vaccine may be over. 
Via The Motley Fool
Topics Cannabis
Exposures COVID-19 Cannabis
58 Biggest Movers From Yesterday
Gainers The Glimpse Group, Inc. (NASDAQ: VRAR) shares jumped 152.3% to settle at $17.66 on Thursday after the company priced its IPO at $7 per share. Pop Culture Group Co., Ltd (... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
30 Stocks Moving In Thursday's Mid-Day Session
Gainers Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 104.6% to $62.00. Pop Culture Group shares jumped 405% on Wednesday after the company priced its IPO at $6 per... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Analyzing CureVac's Unusual Options Activity
CureVac (NASDAQ:CVAC) shares experienced unusual options activity on Thursday. The stock price moved down to $68.53 following the option alert. Sentiment: BULLISH Option Type:... 
Via Benzinga
20 Stocks Moving in Thursday's Pre-Market Session
Gainers Alterity Therapeutics Ltd (NASDAQ: ATHE) shares rose 64% to $2.14 in pre-market trading. Alterity Therapeutics recently said it received EU regulatory guidance for ATH434... 
Via Benzinga
The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) Ambrx Biopharma Inc. (NYSE... 
Via Benzinga
Exposures Product Safety
A Peek Into The Markets: US Stock Futures Up Ahead Of Initial Jobless Claims Data
Pre-open movers U.S. stock futures traded higher in early pre-market trade ahead of initial jobless claims data. The Dow Jones climbed over 200 points on Wednesday, while the S... 
Via Benzinga
Topics Stocks
Exposures US Equities
CureVac Stock Drops After Final Results Confirm Its COVID-19 Vaccine Trails Rivals
The German biotech company CureVac BV (NASDAQ: CVAC) announced on Wednesday after hours the final results of its late-stage COVID-19 vaccine trial showing 48%... 
Via Benzinga
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.